Amyloidosis: Novel Treatments Could Improve Poor Outcomes

Apr 03, 2026

Proteomic profiling of whole tissue sections in cardiac ATTR amyloidosis reveals increased extracellular matrix remodeling

Read more

Apr 03, 2026

Outcomes and predictors of atrial fibrillation in cardiac amyloidosis

Read more

Apr 02, 2026

Podcast: ATTR-CM: What do we know about blood levels of the TTR protein? A discussion with experts

Read more

Apr 01, 2026

Attruby reduces risk of death by 49% in rare heart condition in long-term study

Read more

Apr 01, 2026

Impact of disease-modifying therapies on imaging parameters in cardiac amyloidosis: A systematic review and meta-analysis.

Read more

Mar 30, 2026

Immix Biopharma completes enrollment in AL amyloidosis trial

Read more

Mar 30, 2026

Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy

Read more

Mar 30, 2026

Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

Read more

Mar 30, 2026

New Analyses from Amyloidosis and Hypertension Programs Presented at The American College of Cardiology (ACC) Scientific Sessions 2026

Read more

Mar 28, 2026

Crescentic Glomerulonephritis in a Patient With AL Amyloidosis: A Case Report

Read more

Subscribe to